Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation
Clinical Kidney Journal · 31.05.2023 · 16 (6) · 976-984
DOI: 10.1093/ckj/sfac264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 10.12.2022. Verfasst von Desmond Y H Yap und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wai Hung Charitable Foundation.
Abstract (Originalsprache)
Background
Various glomerular pathologies have been reported in patients who have undergone haematopoietic stem cell transplantation (HSCT), but the data on clinico-pathological correlations and clinical outcome remain limited.
Methods
We analysed the clinical and histopathological data of patients who had biopsy-proven de novo glomerular diseases after HSCT since 1999.
Results
A total of 2204 patients underwent HSCT during the period 1999–2021, and 31 patients (1.4%) developed de novo glomerular diseases after a mean duration of 2.8 ± 2.7 years after HSCT. Fifteen of these patients (48.4%) had graft-versus-host-disease prior to or concomitant with renal abnormalities. Proteinuria and eGFR at the time of kidney biopsy were 4.1 ± 5.3 g/day and 50.8 ± 25.4 mL/min/1.73 m2, respectively. Kidney histopathologic diagnoses included thrombotic microangiopathy (TMA) (38.7%), membranous nephropathy (MN) (25.8%), mesangial proliferative glomerulonephritis (12.9%), minimal change disease (9.7%), focal segmental glomerulosclerosis (9.7%) and membranoproliferative glomerulonephritis (3.2%). Immunosuppressive treatment was given to patients who presented with nephrotic-range proteinuria and/or acute kidney injury, while renin–angiotensin–aldosterone blockade was given to all patients with proteinuria ≥1 g/day, with complete and partial response rates of 54.8% and 19.4%, respectively. One patient with TMA progressed to end-stage kidney disease after 24 weeks, and two patients, one with TMA and one with MN, (6.4%) progressed to chronic kidney disease (CKD) Stage ≥3. Kidney and patient survival rates were 96.6% and 83.5%, respectively, at 5 years.
Conclusion
De novo glomerular diseases with diverse histopathologic manifestations affect 1.4% of patients after HSCT, and approximately 10% develop progressive CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
- Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
- Division of Haematology, Medical Oncology and Haematopoietic Stem Cell Transplantation, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
ORCID-Profile: Davina Lie
Förderung
- Wai Hung Charitable Foundation
Zitieren
APA
Yap, D. Y. H., Lie, D., Lau, T., Tang, A., Chan, G., Chan, T. S. Y., Sim, J., Lie, A. K. W., & Chan, T. M. (2023). Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation. Clinical Kidney Journal, 16(6), 976-984. https://doi.org/10.1093/ckj/sfac264
Vancouver
Yap DYH, Lie D, Lau T, Tang A, Chan G, Chan TSY, et al. Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation. Clinical Kidney Journal. 2023;16(6):976-984. doi:10.1093/ckj/sfac264
BibTeX
@article{Yap2023,
author = {Yap, Desmond Y H and Lie, Davina and Lau, Tiffany and Tang, Alex and Chan, Gavin and Chan, Thomas S Y and Sim, Joycelyn and Lie, Albert K W and Chan, Tak Mao},
title = {Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {6},
pages = {976--984},
doi = {10.1093/ckj/sfac264}
}
EUVIMED